You just read:

Mallinckrodt Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration (FDA) for Terlipressin for the Treatment of Patients with Hepatorenal Syndrome Type 1 (HRS-1)

News provided by

Mallinckrodt Pharmaceuticals

Mar 17, 2020, 06:45 ET